BPTH - Bio-Path Holdings, Inc. Stock Price and Quote

BPTH [NASD]

Index	-	P/E	-	EPS (ttm)	-1.96	Insider Own	0.43%	Shs Outstand	7.96M	Perf Week	-11.46%
Market Cap	11.25M	Forward P/E	-	EPS next Y	-1.68	Insider Trans	0.00%	Shs Float	7.93M	Perf Month	-21.91%
Income	-14.00M	PEG	-	EPS next Q	-0.47	Inst Own	5.80%	Short Float / Ratio	0.81% / 1.75	Perf Quarter	-8.55%
Sales	-	P/S	-	EPS this Y	45.10%	Inst Trans	11.40%	Short Interest	0.06M	Perf Half Y	-56.59%
Book/sh	2.26	P/B	0.62	EPS next Y	8.70%	ROA	-62.20%	Target Price	11.00	Perf Year	-63.99%
Cash/sh	1.69	P/C	0.82	EPS next 5Y	-	ROE	-67.20%	52W Range	1.27 - 4.48	Perf YTD	-7.95%
Dividend	-	P/FCF	-	EPS past 5Y	36.10%	ROI	-	52W High	-68.96%	Beta	1.37
Dividend %	-	Quick Ratio	8.20	Sales past 5Y	-	Gross Margin	-	52W Low	9.17%	ATR	0.12
Employees	10	Current Ratio	8.20	Sales Q/Q	-	Oper. Margin	-	RSI (14)	35.33	Volatility	8.18% 7.68%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-67.90%	Profit Margin	-	Rel Volume	2.75	Prev Close	1.71
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Mar 31 BMO	Payout	-	Avg Volume	36.70K	Price	1.39
Recom	2.00	SMA20	-12.10%	SMA50	-23.96%	SMA200	-48.18%	Volume	100,786	Change	-18.71%

Mar-11-21

Initiated

ROTH Capital

Buy

$13

Nov-13-17

Reiterated

H.C. Wainwright

Buy

$4.50 → $1.50

Aug-10-16

Reiterated

Maxim Group

Buy

$5 → $2

Apr-18-16

Initiated

Rodman & Renshaw

Buy

Jun-02-14

Resumed

Maxim Group

Buy

May-09-14

Initiated

Maxim Group

Buy

Mar-31-23 07:00AM	Bio-Path Holdings Reports Full Year 2022 Financial Results GlobeNewswire -18.71%
Mar-24-23 04:01PM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023 GlobeNewswire
Mar-16-23 07:00AM	Bio-Path Holdings Provides Clinical and Operational Update GlobeNewswire
Dec-28-22 09:59AM	Bio-Path Holdings, Inc. (NASDAQ:BPTH) Q3 2022 Earnings Call Transcript Insider Monkey
Dec-07-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors GlobeNewswire -5.88%
07:00AM	Loading…
Nov-15-22 07:00AM	Bio-Path Holdings Reports Third Quarter 2022 Financial Results GlobeNewswire
Nov-08-22 07:00AM	Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022 GlobeNewswire -7.80%
Nov-07-22 07:00AM	Bio-Path Holdings, Inc. Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement GlobeNewswire -45.96%
Oct-24-22 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients GlobeNewswire
Oct-23-22 09:36AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully Simply Wall St.
Sep-30-22 11:24AM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (BPTH) Newsfile
Sep-06-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference GlobeNewswire
Aug-16-22 07:00AM	Bio-Path Holdings Reports Second Quarter 2022 Financial Results GlobeNewswire
Aug-09-22 07:00AM	Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022 GlobeNewswire
Jun-13-22 12:10PM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq:BPTH) ACCESSWIRE
07:00AM	Loading…
May-17-22 07:00AM	Bio-Path Holdings Reports First Quarter 2022 Financial Results GlobeNewswire
May-16-22 07:51AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Needs To Drive Business Growth Carefully Simply Wall St.
May-10-22 07:00AM	Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022 GlobeNewswire
Apr-13-22 04:30PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH) ACCESSWIRE -17.02%
Apr-12-22 04:01PM	Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-06-22 07:00AM	Bio-Path Holdings Appoints Aline Sherwood to Board of Directors GlobeNewswire
Mar-11-22 07:00AM	Bio-Path Holdings Reports Full Year 2021 Financial Results GlobeNewswire -8.07%
Mar-08-22 04:30PM	Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-04-22 07:00AM	Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022 GlobeNewswire
Jan-05-22 07:00AM	Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference GlobeNewswire
Dec-13-21 07:00AM	Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting GlobeNewswire -7.94%
Dec-06-21 04:22AM	Here's Why We're Not Too Worried About Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Situation Simply Wall St.
Nov-12-21 07:00AM	Bio-Path Holdings Reports Third Quarter 2021 Financial Results GlobeNewswire
Nov-05-21 08:00AM	Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021 GlobeNewswire
Nov-04-21 09:01AM	Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting GlobeNewswire
07:00AM	Loading…
Oct-27-21 07:00AM	Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors GlobeNewswire
Sep-20-21 04:30PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (NASDAQ:BPTH) ACCESSWIRE
Aug-25-21 10:24AM	Bio-Path (BPTH) to Begin Clinical Study on Leukemia Drug Zacks -10.86%
Aug-24-21 11:00AM	Why Bio-Path Holdings Shares Are Surging Higher Today Benzinga +14.94%
08:33AM	Bio-Path Stock Jumps as Leukemia Treatment Candidate Moves to Testing TheStreet.com
07:00AM	Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients GlobeNewswire
Aug-13-21 07:00AM	Bio-Path Holdings Reports Second Quarter 2021 Financial Results GlobeNewswire
Aug-06-21 07:00AM	Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021 GlobeNewswire
Jun-22-21 07:00AM	Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003 GlobeNewswire +9.39%
Jun-15-21 03:22PM	Is Bio-Path Holdings, Inc. (BPTH) A Good Stock To Buy? Insider Monkey -5.30%
Jun-09-21 01:56AM	We Think Bio-Path Holdings (NASDAQ:BPTH) Can Afford To Drive Business Growth Simply Wall St.
May-27-21 08:00AM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) ACCESSWIRE
May-14-21 07:00AM	Bio-Path Holdings Reports First Quarter 2021 Financial Results GlobeNewswire
06:45AM	Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
May-07-21 07:00AM	Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021 GlobeNewswire
Apr-26-21 09:00AM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) ACCESSWIRE
Apr-22-21 07:00AM	Bio-Path Announces Publication in Biomedicines GlobeNewswire
Apr-12-21 07:00AM	Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting GlobeNewswire -8.33%
Apr-05-21 08:03AM	Bio-Path Stock Is Trading Higher As Prexigebersen Triplet Combo Shows Favorable Safety Profile In Acute Myeloid Leukemia Study Benzinga +6.71%
07:00AM	Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia GlobeNewswire
Mar-11-21 07:00AM	Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting GlobeNewswire +15.26%
Mar-10-21 07:00AM	Bio-Path Holdings Reports Full Year 2020 Financial Results GlobeNewswire -6.40%
05:30AM	Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Mar-03-21 04:01PM	Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021 GlobeNewswire
Feb-18-21 04:01PM	Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock GlobeNewswire +9.63%
Feb-16-21 07:15AM	Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock GlobeNewswire -14.89%
Feb-13-21 07:00AM	Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire
Feb-10-21 07:08AM	Bio-Path Quadruples on Receipt of Cancer-Drug Tech Patent TheStreet.com +126.35%
07:00AM	Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology GlobeNewswire
Dec-21-20 02:05PM	Stonegate Capital Partners Updates Coverage On Bio-path Holdings, Inc. (Nasdaq:BPTH) ACCESSWIRE
Dec-11-20 03:48AM	We're Keeping An Eye On Bio-Path Holdings' (NASDAQ:BPTH) Cash Burn Rate Simply Wall St. -8.76%
Nov-19-20 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002 GlobeNewswire
Nov-13-20 07:00AM	Bio-Path Holdings Reports Third Quarter 2020 Financial Results GlobeNewswire -6.69%
Nov-06-20 08:00AM	Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020 GlobeNewswire
Oct-22-20 07:00AM	Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers GlobeNewswire +28.61%
Sep-18-20 12:00PM	Stonegate Capital Partners Updates Coverage On Bio-Path Holdings, Inc. (Nasdaq:BPTH) ACCESSWIRE
Sep-09-20 08:00AM	Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Aug-14-20 07:00AM	Bio-Path Holdings Reports Second Quarter 2020 Financial Results GlobeNewswire -10.00%
Aug-13-20 07:00AM	Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia GlobeNewswire +16.03%
Aug-07-20 08:00AM	Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020 GlobeNewswire
Jun-25-20 11:28PM	Edited Transcript of BPTH.OQ earnings conference call or presentation 15-May-20 12:30pm GMT Thomson Reuters StreetEvents
Jun-17-20 07:30AM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ:BPTH) ACCESSWIRE
May-29-20 08:00AM	Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-15-20 07:00AM	Bio-Path Holdings Reports First Quarter 2020 Financial Results GlobeNewswire -5.38%
May-13-20 05:00PM	Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-08-20 08:00AM	Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020 GlobeNewswire +5.12%
Apr-27-20 09:00AM	Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting GlobeNewswire -6.28%
Apr-13-20 07:00AM	Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting GlobeNewswire +10.23%
Mar-13-20 07:39PM	Edited Transcript of BPTH earnings conference call or presentation 6-Mar-20 1:30pm GMT Thomson Reuters StreetEvents -11.44%
Mar-11-20 07:00AM	Bio-Path Holdings Appoints Ernst & Young as New Auditor GlobeNewswire -10.21%
Mar-06-20 07:00AM	Bio-Path Holdings Reports Full Year 2019 Financial Results GlobeNewswire -12.06%
06:30AM	Bio-Path Holdings, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-20 08:00AM	Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020 GlobeNewswire
Feb-21-20 10:34AM	Does Bio-Path Holdings, Inc.'s (NASDAQ:BPTH) CEO Salary Compare Well With Others? Simply Wall St.
Jan-23-20 09:07AM	Zacks.com featured highlights include: Denny's, Heico, Oasis Midstream Partners, NV5 Global and Bio-Path Zacks
Jan-08-20 08:00AM	Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook GlobeNewswire
Dec-06-19 09:25AM	Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (Nasdaq: BPTH) ACCESSWIRE
Dec-05-19 09:42PM	Edited Transcript of BPTH earnings conference call or presentation 15-Nov-19 1:30pm GMT Thomson Reuters StreetEvents -6.42%
Dec-04-19 12:00PM	Bio-Path (BPTH) Upgraded to Buy: Here's What You Should Know Zacks +15.55%
Nov-26-19 08:00AM	Bio-Path Holdings Announces Successful Completion of Safety Testing in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia GlobeNewswire -5.56%
Nov-25-19 02:11PM	Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire
Nov-21-19 11:30AM	Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market GlobeNewswire -22.24%
08:00AM	Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 GlobeNewswire
Nov-15-19 07:00AM	Bio-Path Holdings Reports Third Quarter 2019 Financial Results GlobeNewswire
Nov-08-19 08:00AM	Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019 GlobeNewswire
Oct-29-19 06:47AM	Investors Who Bought Bio-Path Holdings (NASDAQ:BPTH) Shares Five Years Ago Are Now Down 98% Simply Wall St.
Oct-16-19 02:29PM	Houston biotech co. avoids stock exchange delisting amid board shakeup American City Business Journals
Oct-15-19 08:00AM	Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors GlobeNewswire
Sep-25-19 08:00AM	Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent GlobeNewswire
Sep-14-19 09:36AM	Is Bio-Path Holdings, Inc. (NASDAQ:BPTH) Excessively Paying Its CEO? Simply Wall St.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Upgrade your FINVIZ experience